Pre-symptomatic markers for diseases associated with transmissible spongiform encephalopathies
View Patent ↗Markers for TSE that are present prior to formation of detectable pathological prion protein are useful to detect this infection prior to clinical signs. Additional markers are useful to detect the stage of TSE infection and distinguish it from other conditions which have similar clinical symptoms. Determinations on isolated cell preparations are particularly useful, especially those derived from peripheral (non-brain) sources.
1. A method to assess a likelihood that a subject has been infected with a transmissible spongiform encephalopathy (TSE) which method comprises:
determining, in a sample of brain tissue, cerebrospinal fluid or an isolated brain cell preparation taken from said subject before clinical signs of infection appear, the level of expression of the marker serum amyloid A3 (SAA3) in combination with the level of expression of at least two of the additional markers L-selectin, MIP-1α, CX3CR1 and ImmResG1,
whereby an increase in the level of expression of each marker of the combination in said sample at least 2 fold as compared to the level in a corresponding control sample indicates the likelihood that the subject has been infected with TSE.
2. The method of claim 1 wherein the brain cell preparation is of the microglia.
3. The method of claim 1 wherein said additional marker includes L-selectin.
4. The method of claim 1 wherein said additional marker includes MIP-1α.
5. The method of claim 1 wherein said additional marker includes CX3CR1.
6. The method of claim 1 wherein said additional marker includes ImmResG1.